HAE Haemonetics Corporation
Company Analysis
Latest News
John Rogers' Ariel Investments Discloses New $155M Haemonetics Stake
Ariel Investments, the firm founded by prominent value investor John Rogers, has initiated a new position in Haemonetics Corp. (HAE), a global medical...
🟢 Haemonetics is trading 6.2% up in after-hours trading after CSL Plasma supply agreement
Haemonetics is trading 6.2% up at $114.90 after investors continued reacting to its non-exclusive CSL Plasma supply agreement. - The agreement allows CSL to...
🟢 Haemonetics is trading 6.2% up in pre-market after CSL Plasma returns to NexSys platform
Haemonetics is trading 6.18% up at $111.12 after investors continued reacting to its non-exclusive supply agreement with CSL Plasma. - The agreement allows...
🟢 Haemonetics is trading 16.2% up today after disclosing U.S. supply agreement with CSL Plasma
Haemonetics is trading 16.2% up at $104.84 after disclosing an August 14, 2026 non-exclusive U.S. supply agreement with CSL Plasma. - CSL Plasma may use...
Haemonetics Wins Back CSL Plasma After a Bitter 2021 Divorce — But Can a Non-Exclusive Deal Justify a 10% Rally?
Shares of Haemonetics surged 10.2% to $99.50 on Tuesday after the company disclosed it had signed a new U.S. supply agreement with CSL Plasma, the world's...
🟢 Haemonetics is trading 10.22% up in pre-market after disclosing CSL Plasma supply agreement
Haemonetics is trading 10.22% up at $99.50 after disclosing a non-exclusive U.S. supply agreement with CSL Plasma on August 18, 2026. - The agreement covers...
🟢 Haemonetics is trading 6.4% up in pre-market; no clear immediate catalyst identified
Haemonetics is trading at $96.06 (+6.41%) after no clearly identifiable company-specific announcement on August 18, 2026. - The latest major catalyst was the...
🟢 Haemonetics is trading 4.4% up today after BofA raised its price target to $100
Haemonetics is trading 4.4% higher at $91.06 after BofA Securities raised its price target to $100 from $93 on August 12, 2026; the source does not explicitly...
🟢 Haemonetics is trading 5% up today after earnings beat and raised FY2027 guidance
Haemonetics is trading 5% up now at $87.79 after reporting first-quarter fiscal 2027 revenue of $339.4 million and adjusted EPS of $1.14, exceeding the $1.07...
Haemonetics' first quarter revenue grew 5.6% to $339.4M, prompting a raise in FY2027 guidance.
Haemonetics reported first quarter fiscal 2027 revenue of $339.4 million, an increase of 5.6% year-over-year, and adjusted earnings per share of $1.14, up...
Haemonetics Corporation Q2 2026 Earnings Preview: What Analysts Expect on August 06, 2026
Haemonetics is expected to report Q2 2026 revenue of $327.9 million and earnings per share of $1.07, with the current stock price of $85.54 trading close to...
Haemonetics Appoints Martin Madaus to Board; Shareholders Approve Expanded Incentive Plan
Haemonetics announced the election of Dr. Martin Madaus to its Board of Directors, effective July 24, 2026. Concurrently, following its 2026 annual shareholder...
🟢 Haemonetics is trading 4.1% up today amid broad healthcare sector strength
Haemonetics is trading 4.1% up at $83.16 as the stock outperforms the broader market amid a strong move across healthcare peers. • There are no fresh...
🟢 Haemonetics is trading 4.2% up today amid a broad healthcare sector rally
Haemonetics is trading 4.2% up at $79.92 as the stock moves in tandem with a broad healthcare sector rally. • The upward momentum is driven by strong earnings...